MonoMac6 [MM6]
Export
monocytic leukemia (AML) cell line
Cell Type:
Monocyte
Tissue Origin:
blood
Species:
human
Research Area:
Immunotherapy / Hematology
Cell Characteristics:
Suspension
Transfection Information
Lonza Optimized Protocol
Optimization Guideline
Filter:
Any Substrate
Any Platform
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols
or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our
optimization strategy
to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol
Kit
Program
Cells
Efficiency
Viable Cells
Substrate
Format
Platform
R
T-001
1e6
45%
95%
Plasmid (general)
5 µg
100 µl
I/II/2b
R
U-001
1e6
44%
90%
Plasmid (general)
5 µg
100 µl
I/II/2b
V
U-001
1e6
53%
85%
Plasmid (general)
5 µg
100 µl
I/II/2b
V
U-005
1e6
70%
50%
Plasmid (general)
5 µg
100 µl
I/II/2b
V
V-001
1e6
30-60%
70%
Plasmid (general)
µg
100 µl
I/II/2b
C
X-001
2e6
64%
49%
Plasmid (general)
2 µg
100 µl
I/II/2b
L
X-001
2e6
52%
49%
Plasmid (general)
2 µg
100 µl
I/II/2b
V
U-005
2e6
50%
56%
Plasmid (general)
2 µg
100 µl
I/II/2b
Citations
Dynamic protein associations define two phases of IL-1beta transcriptional activation
Categories:
Transfection
Authors:
Zhang Y, Saccani S, Shin H, Nikolajczyk BS
In:
J Immunol (2008) 181(1): 503-12
PPARgamma regulated ABCG2 expression confers cytoprotection to human dendritic cells
Categories:
Transfection
Authors:
Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, Jeney V, Ozvegy-Laczka C, Szanto A, Barta E, Balla J, Sarkadi B, Nagy L
In:
J Biol Chem (2006) 281(33): 23812-23
Identification of a novel tumor necrosis factor -responsive region in the NCF2 promoter
Categories:
Transfection
Authors:
Gauss KA, Bunger PL, Larson TC, Young CJ, Nelson-Overton LK, Siemsen DW and Quinn MT
In:
J Leukoc Biol (2005) 77(2): 267-278